دورية أكاديمية
أعرض في EDS

Durable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception?

التفاصيل البيبلوغرافية
العنوان: Durable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception?
المؤلفون: van Bergen CA; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Verdegaal EM; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Honders MW; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Hoogstraten C; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Steijn-van Tol AQ; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., de Quartel L; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., de Jong J; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Meyering M; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Falkenburg JH; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Griffioen M; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Osanto S; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
المصدر: PloS one [PLoS One] 2014 Jan 15; Vol. 9 (1), pp. e85198. Date of Electronic Publication: 2014 Jan 15 (Print Publication: 2014).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Remission Induction* , Stem Cell Transplantation*, Carcinoma, Renal Cell/*therapy , Graft vs Host Disease/*physiopathology , Kidney Neoplasms/*therapy, Female ; Humans ; Middle Aged ; Transplantation, Homologous
مستخلص: Allogeneic stem cell transplantation (alloSCT) followed by donor lymphocyte infusion (DLI) can be applied as immunotherapeutic intervention to treat malignant diseases. Here, we describe a patient with progressive metastatic clear cell renal cell carcinoma (RCC) who was treated with T cell depleted non-myeloablative alloSCT and DLI resulting in disease regression accompanied by extensive graft versus host disease (GVHD). We characterized the specificity of this immune response, and detected a dominant T cell population recognizing a novel minor histocompatibility antigen (MiHA) designated LB-FUCA2-1V. T cells specific for LB-FUCA2-1V were shown to recognize RCC cell lines, supporting a dominant role in the graft versus tumor (GVT) reaction. However, coinciding with the gradual disappearance of chronic GVHD, the anti-tumor effect declined and 3 years after alloSCT the metastases became progressive again. To re-initiate the GVT reaction, escalating doses of DLI were given, but no immune response could be induced and the patient died of progressive disease 8.5 years after alloSCT. Gene expression studies illustrated that only a minimal number of genes shared expression between RCC and professional antigen presenting cells but were not expressed by non-malignant healthy tissues, indicating that in patients suffering from RCC, GVT reactivity after alloSCT may be unavoidably linked to GVHD.
References: N Engl J Med. 2000 Sep 14;343(11):750-8. (PMID: 10984562)
J Immunol. 2000 Dec 1;165(11):6229-34. (PMID: 11086057)
Biol Blood Marrow Transplant. 2012 Sep;18(9):1353-67. (PMID: 22796533)
Cancer Res. 2011 Aug 1;71(15):5111-22. (PMID: 21659460)
PLoS One. 2011;6(6):e21699. (PMID: 21738768)
Tissue Antigens. 2003 Nov;62(5):378-84. (PMID: 14617044)
J Exp Med. 2004 Apr 5;199(7):885-94. (PMID: 15051765)
Am J Hum Genet. 2007 Sep;81(3):559-75. (PMID: 17701901)
Cancer. 1998 Dec 15;83(12):2468-74. (PMID: 9874450)
Trends Immunol. 2008 Dec;29(12):624-32. (PMID: 18952501)
Cancer Immunol Immunother. 2009 Mar;58(3):429-39. (PMID: 18719914)
Clin Cancer Res. 2008 Aug 15;14(16):5260-9. (PMID: 18698046)
Expert Opin Biol Ther. 2011 Jun;11(6):763-73. (PMID: 21417772)
Blood. 2004 Jan 1;103(1):347-52. (PMID: 12969970)
Cancer. 2008 Jul 15;113(2):336-46. (PMID: 18521898)
Eur J Biochem. 2001 Jun;268(11):3321-31. (PMID: 11389735)
Exp Hematol. 2003 Oct;31(10):865-72. (PMID: 14550801)
Haematologica. 2012 Aug;97(8):1196-204. (PMID: 22419570)
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14581-6. (PMID: 19666478)
J Clin Invest. 2008 Mar;118(3):1099-109. (PMID: 18292810)
Expert Rev Anticancer Ther. 2011 Jun;11(6):901-11. (PMID: 21707287)
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S33-8. (PMID: 21195308)
Science. 1999 Jul 16;285(5426):412-5. (PMID: 10411505)
Cancer Res. 2010 Nov 15;70(22):9073-83. (PMID: 21062987)
Annu Rev Med. 2003;54:491-512. (PMID: 12414918)
Blood. 2008 Mar 15;111(6):3286-94. (PMID: 18178869)
Haematologica. 2006 Nov;91(11):1559-62. (PMID: 17082014)
Proc Natl Acad Sci U S A. 1972 Feb;69(2):383-7. (PMID: 4333982)
Cancer Res. 1995 Aug 15;55(16):3654-8. (PMID: 7627975)
Haematologica. 2004 May;89(5):599-605. (PMID: 15136224)
تواريخ الأحداث: Date Created: 20140124 Date Completed: 20141229 Latest Revision: 20211021
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC3893183
DOI: 10.1371/journal.pone.0085198
PMID: 24454818
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0085198